Search - tctmd.com

Displaying 61 - 80 of 126

Sort: Relevancy | Date

Presentation TCT 2016

Start With a Three-way Debate: Heparin Monotherapy Is the Optimal Procedural Anticoagulant in STEMI Patients Undergoing Primary PCI!

Presenter: A. Michael Lincoff, Franz-Josef Neumann

October 30, 2016

Presentation TCT 2016

Reversal of Chronic Anticoagulation: When, What, and How Effective?

Presenter: Paul A. Gurbel, James A. Reiffel

October 30, 2016

Presentation TCT 2016

Chronic Oral Anticoagulants: Limitations, Use Recommendations, and Investigational Agents

Presenter: Paul A. Gurbel, Christopher B. Granger

October 30, 2016

Presentation TCT 2016

Antiplatelet Agents: Limitations, Use Recommendations, and Investigational Agents

Presenter: David J. Moliterno

October 30, 2016

Presentation TCT 2016

Procedural Anticoagulants: Limitations, Use Recommendations and, Investigational Agents

Presenter: Paul A. Gurbel, Harvey D. White

October 30, 2016

News Opinion Editor's Corner TCT 2015

My Takeaways From TCT 2015

Shelley Wood

October 20, 2015

Presentation TCT 2015

Is There a Role for Oral Anticoagulants After PCI?

Presenter: Eric R. Bates, Neal S. Kleiman, C. Michael Gibson

October 15, 2015

Presentation TCT 2015

Vorapaxar: Lessons From the Randomized Trials in ACS and for Secondary Prevention

Presenter: Eric R. Bates, Neal S. Kleiman, Ori Ben-Yehuda

October 15, 2015

Presentation TCT 2015

Should You Bridge in Stented Patients Needing Surgery?

Presenter: Eric R. Bates, Neal S. Kleiman, David F. Kong

October 15, 2015

Presentation TCT 2015

What Is the Optimal Anticoagulant for Transradial PCI?

Presenter: Olivier F. Bertrand, John A. Bittl

October 15, 2015

News Conference News TCT 2015

BRAVO 3: Bivalirudin Similar to Heparin in Transfemoral TAVR

Yael L. Maxwell

October 15, 2015

Presentation TCT 2015

Can We Drop Aspirin? Pharmacodynamic Insights on Adding an Oral Anticoagulant to Antiplatelet Therapy With and Without Aspirin

Presenter: Pascal Vranckx, Freek W.A. Verheugt

October 14, 2015

News Conference News TCT 2015

Discussion Highlights Merits, Limitations of Small Trials

Yael L. Maxwell

October 13, 2015

Presentation TCT 2015

Procedural Anticoagulants in Sweden: Results From the SCAAR Registry and Rationale for VALIDATE-SWEDEHEART

Presenter: John A. Bittl, Robert A. Harrington, David Erlinge

October 12, 2015

Presentation TCT 2015

I Dont Believe Bivalirudin Should Routinely Be Used as the First-line Anticoagulant in Primary PCI!

Presenter: Nick Curzen, Ajay J. Kirtane, David J. Cohen

October 12, 2015

News Conference News TCT 2015

LAA Closure Trials Illustrate Evolution of Devices, Trial Design

October 12, 2015

Presentation TCT 2015

How Good Is LAA Closure Compared to Oral Anticoagulants? Results of Studies

Presenter: Russell A. Brandwein, Elizabeth M Perpetua

October 11, 2015

News Conference News TCT 2015

Use of LAA Occlusion in Low-Risk Patients Debated

Todd Neale

October 11, 2015

News Conference News TCT 2015

Cath Lab Economics: Pursuit of a Light at the End of the Tunnel

Nicole Lou

October 11, 2015

News Conference News TCT 2014

Thoughtful Insights at TCT: Uncertainty Surrounds Antithrombotic Therapy in PCI Patients Who Require Anticoagulation

Todd Neale

October 10, 2014

Advertisement

Start With a Three-way Debate: Heparin Monotherapy Is the Optimal Procedural Anticoagulant in STEMI Patients Undergoing Primary PCI!

Reversal of Chronic Anticoagulation: When, What, and How Effective?

Chronic Oral Anticoagulants: Limitations, Use Recommendations, and Investigational Agents

Antiplatelet Agents: Limitations, Use Recommendations, and Investigational Agents

Procedural Anticoagulants: Limitations, Use Recommendations and, Investigational Agents

My Takeaways From TCT 2015

Is There a Role for Oral Anticoagulants After PCI?

Vorapaxar: Lessons From the Randomized Trials in ACS and for Secondary Prevention

Should You Bridge in Stented Patients Needing Surgery?

What Is the Optimal Anticoagulant for Transradial PCI?

BRAVO 3: Bivalirudin Similar to Heparin in Transfemoral TAVR

Can We Drop Aspirin? Pharmacodynamic Insights on Adding an Oral Anticoagulant to Antiplatelet Therapy With and Without Aspirin

Discussion Highlights Merits, Limitations of Small Trials

Procedural Anticoagulants in Sweden: Results From the SCAAR Registry and Rationale for VALIDATE-SWEDEHEART

I Dont Believe Bivalirudin Should Routinely Be Used as the First-line Anticoagulant in Primary PCI!

LAA Closure Trials Illustrate Evolution of Devices, Trial Design

How Good Is LAA Closure Compared to Oral Anticoagulants? Results of Studies

Use of LAA Occlusion in Low-Risk Patients Debated

Cath Lab Economics: Pursuit of a Light at the End of the Tunnel

Thoughtful Insights at TCT: Uncertainty Surrounds Antithrombotic Therapy in PCI Patients Who Require Anticoagulation

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content